D
Denis Smith
Researcher at University of Bordeaux
Publications - 121
Citations - 5755
Denis Smith is an academic researcher from University of Bordeaux. The author has contributed to research in topics: Bevacizumab & Colorectal cancer. The author has an hindex of 22, co-authored 110 publications receiving 3971 citations. Previous affiliations of Denis Smith include French Institute of Health and Medical Research.
Papers
More filters
Journal ArticleDOI
Sunitinib malate for the treatment of pancreatic neuroendocrine tumors.
Eric Raymond,Laetitia Dahan,Jean-Luc Raoul,Yung-Jue Bang,Ivan Borbath,Catherine Lombard-Bohas,Juan W. Valle,Peter Metrakos,Denis Smith,Aaron I. Vinik,Jen-Shi Chen,Dieter Hörsch,Pascal Hammel,Bertram Wiedenmann,Eric Van Cutsem,Shem Patyna,Dongrui Ray Lu,C. Blanckmeister,Richard C. Chao,Philippe Ruszniewski +19 more
TL;DR: Continuous daily administration of sunitinib at a dose of 37.5 mg improved progression-free survival, overall survival, and the objective response rate as compared with placebo among patients with advanced pancreatic neuroendocrine tumors.
Journal ArticleDOI
Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer.
Thierry André,Kai-Keen Shiu,Tae Won Kim,Benny Vittrup Jensen,Lars Henrik Jensen,Cornelis J. A. Punt,Denis Smith,Rocio Garcia-Carbonero,Manuel Benavides,Peter Gibbs,Christelle De La Fouchardiere,Fernando Rivera,Elena Elez,Johanna C. Bendell,Dung T. Le,Takayuki Yoshino,Eric Van Cutsem,Ping Yang,Mohammed Z.H. Farooqui,Patricia Marinello,Luis A. Diaz,Keynote Investigators +21 more
TL;DR: Pembrolizumab led to significantly longer progression-free survival than chemotherapy when received as first-line therapy for MSI-H-dMMR metastatic colorectal cancer, with fewer treatment-related adverse events.
Journal ArticleDOI
First-line selective internal radiotherapy plus chemotherapy versus chemotherapy alone in patients with liver metastases from colorectal cancer (FOXFIRE, SIRFLOX, and FOXFIRE-Global): a combined analysis of three multicentre, randomised, phase 3 trials
Harpreet Wasan,Peter Gibbs,Navesh K Sharma,Julien Taieb,Volker Heinemann,Jens Ricke,Marc Peeters,Michael Findlay,Andrew Weaver,Jamie Mills,Charles Wilson,Richard Adams,Anne Francis,Joanna Moschandreas,P S Virdee,Peter Dutton,Sharon Love,Val Gebski,Alastair Gray,Andrew Bateman,Claire Blesing,Ewan Brown,Ian Chau,Sebastian Cummins,David Cunningham,Stephen Falk,Maher Hadaki,Marcia Hall,Tamas Hickish,Joanne Hornbuckle,F. Lofts,Sarah Lowndes,Astrid Mayer,Matthew Metcalfe,Gary Middleton,Amir Montazeri,Rebecca Muirhead,Andreas Polychronis,Colin Purcell,Paul Ross,Ricky A. Sharma,Liz Sherwin,David J. Smith,Rubin Soomal,Daniel Swinson,Axel Walther,Harpreet Wasan,Greg Wilson,Pradip Amin,Bruna Angelelli,Jacques Balosso,Alex Beny,Daniel Bloomgarden,Evelyn Boucher,Michael P. Brown,Harald-Robert Bruch,James Bui,Matthew Burge,Giuseppe Cardaci,James Carlisle,Seungjean Chai,Yi-Jen Chen,Patrick Chevallier,Michael Chuong,Stephen Clarke,Andrew L. Coveler,Michael Craninx,Thierry Delanoit,Amélie Deleporte,Paul Eliadis,Francis Facchini,Tom Ferguson,Michel Ferrante,Gary Frenette,Jacob Frick,Vinod Ganju,Michael Garofalo,Karen Geboes,Gerald Gehbauer,Benjamin George,Ravit Geva,Michael Gordon,Kate Gregory,Seza Gulec,James Hannigan,Guy van Hazel,Norman Isaac Heching,Thomas Helmberger,Alain Hendlisz,Koen Hendrickx,Matthew Holtzman,Richard Isaacs,Christopher Jackson,Philip T. James,Adeel Kaiser,Chris Karapetis,Andreas Kaubisch,Yon-Dschun Ko,H. Kröning,Frank Lammert,Winston Liauw,Steven Limentani,Samy Louafi,Marc De Man,Jeffrey Margolis,Robert C.G. Martin,Andrea Martoni,Gavin Marx,Marco Matos,E Monsaert,Veerle Moons,Louise M. Nott,Arnd Nusch,Anne O'Donnell,Howard Ozer,Siddarth A Padia,Nick Pavlakis,David Perez,Stefan Pluntke,Marc Polus,Alex Powell,Marc Pracht,Timothy J. Price,David Ransom,Christine Rebischung,Karsten Ridwelski,Jorge Riera-Knorrenschild,Hanno Riess,William S. Rilling,Bridget A. Robinson,Javier Rodríguez,Federico Sanchez,Tilmann Sauerbruch,Michael Savin,Klemens Scheidhauer,Elyse Schneiderman,Grant Seeger,Eva Segelov,Einat Shaham Schmueli,Adi Shani,Jenny Shannon,Navesh K. Sharma,Stephen Shibata,Nimit Singhal,Denis Smith,Randall Smith,Salomon M. Stemmer,Oliver Stötzer,Andrew Strickland,Klaus Tatsch,Eric Terrebonne,Thomas Tichler,Ursula Vehling-Kaiser,Ruth Vera-Garcia,Thomas J Vogl,Euan Walpole,Eric Wang,Samuel Whiting,Ido Wolf,Steven Ades,Morteza Aghmesheh,Miklos Auber,Hubert Ayala,Patrick McKay Boland,Eveline Bouche,Charles Bowers,Christoph Bremer,M. Burge,Ana Ruíz Casado,Prasad Cooray,Martin R. Crain,Maike De Wit,Kyran Dowling,Aurelie Durand,Sandrine Faivre,Kynan Feeney,Thomas W. Ferguson,Aurelie Ferru,Maria Fragoso,Cristina Granetto,Pascal Hammel,Richard Issacs,Renuka Iyer,Yeul Hong Kim,Jin-Tung Liang,Lionel Lim,Jin Hwang Liu,Gianluca Masi,Stefania Mosconi,Gianmauro Numico,Lynn Ratner,Han Sae-Won,Madhu Sudan Singh,Patricia Stoltzfus,Iain Tan,Antonio Trogu,Craig Underhill,Mark Westcott +197 more
TL;DR: Data suggest selective internal radiotherapy (SIRT) in third-line or subsequent therapy for metastatic colorectal cancer has clinical benefit in patients with coloreCTal liver metastases with liver-dominant disease after chemotherapy.
Journal ArticleDOI
Phase iii randomised comparison of gemcitabine (gem) with gemcitabine plus capecitabine (gem-cap) in patients with advanced pancreatic cancer
John P. Neoptolemos,Ian Chau,Deborah D. Stocken,C Davies,J Dunn,Juan W. Valle,Denis Smith,W Steward,P Harper,D Cunninghamon +9 more
Journal ArticleDOI
Pembrolizumab versus chemotherapy for microsatellite instability-high/mismatch repair deficient metastatic colorectal cancer: The phase 3 KEYNOTE-177 Study.
Thierry André,Kai-Keen Shiu,Tae Won Kim,Benny Vittrup Jensen,Lars Henrik Jensen,Cornelis J. A. Punt,Denis Smith,Rocio Garcia-Carbonero,Manuel Benavides,Peter Gibbs,Christelle De La Fouchardiere,Fernando Rivera,Elena Elez,Johanna C. Bendell,Dung T. Le,Takayuki Yoshino,Ping Yang,Mohammed Z.H. Farooqui,Patricia Marinello,Luis A. Diaz +19 more
TL;DR: LBA4 is a phase 3, randomized open-label study evaluating the efficacy and safety of pembrolizumab (pembro) versus standard of care chemotherapy ± bevacIZumab o...